<DOC>
	<DOCNO>NCT00000953</DOCNO>
	<brief_summary>To compare efficacy oral sorivudine ( brovavir ) oral acyclovir treatment localize herpes zoster HIV-infected patient . HIV-infected patient high risk herpesvirus infection , include varicella-zoster virus ( VZV ) infection , also call shingle . Acyclovir , approve drug , widely use treat VZV infection HIV population . Since data control study available define role antiviral therapy VZV infection HIV-infected patient , study need test relative efficacy brovavir , experimental antiviral drug , versus acyclovir .</brief_summary>
	<brief_title>Comparison Brovavir Versus Acyclovir Treatment Herpes HIV-Infected Patients</brief_title>
	<detailed_description>HIV-infected patient high risk herpesvirus infection , include varicella-zoster virus ( VZV ) infection , also call shingle . Acyclovir , approve drug , widely use treat VZV infection HIV population . Since data control study available define role antiviral therapy VZV infection HIV-infected patient , study need test relative efficacy brovavir , experimental antiviral drug , versus acyclovir . One hundred-eighty patient randomize receive either brovavir acyclovir follow : brovavir match placebo daily acyclovir match placebo five time daily . Treatment continue 10 day . Entry study must occur within 72 hour lesion development . Patients follow person daily regular interval study drug administration day 14 , 21 , 28 , monthly telephone 11 month thereafter .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Sorivudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Medication concurrent condition ( e.g. , insulin , antihypertensive , bronchodilator , digoxin ) antibacterial antifungal treat concurrent infection sit superinfection zoster lesion . Antiinflammatory , analgesic ( include narcotic analgesic ) , antipyretic agent . Antidepressants antipsychotic amitriptyline and/or fluphenazine . Nerve block . AZT , ddI , ddC , amantadine . Lowdose corticosteroid treatment underlie ( zosterrelated ) disease . Immune modulators without varicellazoster virus activity ( e.g. , GMCSF , gp160 vaccine ) . Patients must : HIV infection . Localized , cutaneous herpes zoster ( shingle ) . Zosterassociated rash present 3 few day prior entry . Prior Medication : Allowed : Zidovudine . ddI . ddC . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Chickenpox . Evidence visceral dissemination ( organ involvement , i.e. , brain , liver , lung ) and/or cutaneous dissemination ( 20 vesicle dermatomes beyond contiguous dermatome ) zoster . Zosterlike lesion cause organism VZV ( e.g. , HSV , enterovirus , Mycoplasma ) . Bacterial superinfection zoster lesion . Zosteriform lesion previously treat topical antiviral agent . Acute , lifethreatening opportunistic infection require treatment ( ongoing suppressive prophylactic maintenance therapy ganciclovir foscarnet permit ) . Concurrent severe disease may either impair ability take oral medication capsule tablet form limit survival 10day treatment period acute phase followup ( 28 day ) . Suspected acute deterioration renal hepatic function . Mental impairment precludes ability comply protocol . Any condition would render patient unsuitable treatment . Concurrent Medication : Excluded acute phase study : Antiviral medication AZT , ddI , ddC , antiParkinson 's drug ( i.e. , amantadine ) . Interferon . Isoprinosine . Levamisole . Transfer factor . Topical virucidal agent , oxidize agent , DMSO , cell divisionstimulating/healing agent , astringent . Topical anesthetic ( capsaicin xylocaine ) . Topical cream ointment may interfere evaluation zoster lesion . Cimetidine . Fluorouracil derivative , flucytosine , cyclophosphamide ( drug administration 2 week thereafter ) . Highdose corticosteroid . Anticoagulant therapy ( heparin lock lowdose warfarin sodium permit ) . Probenecid derivative . Treatment acute , lifethreatening opportunistic infection ( suppressive prophylactic maintenance therapy ganciclovir foscarnet permit ) . Use follow drug discourage longterm phase study : Antiviral agent VZV activity . Immunomodulators presume VZV activity . VZV immune globulin . Capsaicin . Cimetidine . Patients follow prior condition exclude : History immediate hypersensitivity serum sickness reaction idiosyncratic reaction ( hepatic necrosis StevensJohnson syndrome ) nucleoside analog antiviral agent anticancer therapy cytolytic agent . Prior Medication : Excluded within 1 month prior entry : Any investigational drug treatment license indication ( ddI ddC ) . Excluded within 2 week prior entry : Any systemic antiviral therapy , include ganciclovir , foscarnet , vidarabine , acyclovir , ribavirin . Any antiretroviral drug zidovudine , ddI , ddC . Immune globulin ( e.g. , IgG , VZIG ) . Excluded within 72 hour prior entry : Cyclophosphamide . Flucytosine . Fluorouracil derivative . Alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Herpes Zoster</keyword>
	<keyword>Acyclovir</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>sorivudine</keyword>
</DOC>